CIPLA LTD.

Cipla Ltd has been assigned an Environmental, Social, and Governance (ESG) rating of 68 by Niche, a SEBI-registered ESG Rating Provider. The company was notified of this rating indirectly through alerts disseminated by BSE on September 17, 2026. Niche communicated the rating directly to NSE on September 11, 2026, and to BSE on September 17, 2026. Cipla has not received direct communication from Niche regarding this rating.

Cipla Limited, through its subsidiary Invagen Pharmaceuticals Inc., has entered into a strategic partnership with Qilu Pharmaceutical Co., Ltd. for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda (pembrolizumab), in the United States. Qilu will handle development, regulatory registration, and supply, while Cipla USA will manage commercialization. This collaboration aims to enhance access to advanced biologic therapies for cancer patients and strengthen Cipla's oncology portfolio. The partnership leverages Qilu's development expertise and Cipla's commercial presence in the US market, with the goal of providing a high-quality, affordable pembrolizumab biosimilar.

Cipla Ltd has issued a notice to its shareholders and creditors regarding the Scheme of Amalgamation (by Absorption) of Inzpera Healthsciences Limited with Cipla Limited. This follows an order from the National Company Law Tribunal (NCLT), Mumbai Bench, dated August 18, 2026. Shareholders and creditors are being informed via electronic and physical modes. They have 30 days from receipt of the notice to submit any representations to the NCLT. Failure to respond will be presumed as no objection to the scheme. The NCLT has dispensed with the meetings of equity shareholders and unsecured creditors of Cipla Limited.

Cipla Limited has entered into an exclusive license and supply agreement with Sino Biopharmaceutical Limited (SBP Group) for Rolditamig Deuderuxtecan (TQB2102), a potential best-in-class HER2 bispecific antibody-drug conjugate (ADC). This collaboration grants Cipla exclusive rights to develop and commercialize TQB2102 in India, South Africa, and five other emerging markets. Cipla will manage local clinical development, regulatory affairs, and commercialization, while SBP Group's subsidiary, CTTQ, will handle manufacturing and supply. TQB2102 is being evaluated for HER2-expressing cancers, including HER2-low advanced breast cancer, and has received Breakthrough Therapy Designations in China. The partnership aims to accelerate development and patient access to this innovative oncology therapy in the licensed territories.

Cipla Ltd announced that its wholly-owned subsidiary, InvaGen Pharmaceuticals Inc., received communication from the USFDA regarding an inspection conducted at its Unit 3 manufacturing facility in Long Island, New York. The inspection, which took place from July 13-17, 2026, has been classified by the USFDA as Voluntary Action Indicated (VAI). This classification suggests that while the inspection identified some issues, they do not currently warrant mandatory regulatory action, indicating a positive outcome for the facility's compliance status.

Cipla Ltd. has announced a restructuring of its group structure involving its joint venture, Aspergen Limited, India. Aspergen Limited has acquired 100% stake in Aspergen Inc., USA, a step-down subsidiary, from Cipla (EU) Limited and Kemwell Biopharma UK Limited. Consequently, Aspergen Inc., USA is now a wholly owned subsidiary of Aspergen Limited, India. Cipla states there is no change in its economic interest in Aspergen Inc., USA due to this restructuring, which aims to rationalize and simplify the group's structure. Details regarding the quantitative/qualitative effects and benefits to promoters are enclosed as per SEBI regulations.

Cipla Ltd announced that its manufacturing facility in Pithampur, India, underwent a follow-up current Good Manufacturing Practices (cGMP) inspection by the USFDA from August 17-25, 2026. Following the inspection, the company received seven observations in Form 483. Cipla has stated its commitment to working closely with the USFDA to address these observations comprehensively within the stipulated timeframe. This follows previous intimations regarding the facility's regulatory status.

Cipla Limited has received an order from the Hon'ble National Company Law Tribunal (NCLT), Mumbai Bench, approving the Scheme of Amalgamation of its wholly-owned subsidiary, Inzpera Healthsciences Limited, with Cipla Limited. The order, dated August 18, 2026, allows the amalgamation with specific directions. The scheme was approved by the respective Boards on March 19, 2026, with an Appointed Date of April 1, 2026. The amalgamation aims to consolidate resources, improve operational efficiency, enhance shareholder value, and reduce compliance costs.

Cipla Ltd has disclosed its Environmental, Social, and Governance (ESG) ratings from SES ESG Research Private Limited and NSE Sustainability Ratings & Analytics Limited. For FY 2025-26, SES assigned a rating of 69.9 (Grade B), an improvement from 69.3 (Grade B) in FY 2024-25. NSE rated Cipla at 67 (Aspiring) for FY 2025-26, a slight decrease from 69 (Aspiring) in FY 2024-25. The company attributes the marginal decline in the NSE rating potentially to a product recall by its subsidiary, Cipla USA Inc., in January 2026. These ratings are provided by SEBI registered ESG Rating Providers.

Cipla Ltd announced that its wholly-owned subsidiary, InvaGen Pharmaceuticals, Inc., located in Hauppauge, New York, USA, has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA). This report indicates the closure of the Pre-Approval Inspection (PAI) that was conducted at the facility. The intimation follows a previous disclosure on February 10th, 2026, regarding the PAI.